Global Pegfilgrastim Biosimilar Market Growth 2023-2029

February 2023 | 93 pages | ID: G47217FBCF24EN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.

LPI (LP Information)' newest research report, the “Pegfilgrastim Biosimilar Industry Forecast” looks at past sales and reviews total world Pegfilgrastim Biosimilar sales in 2022, providing a comprehensive analysis by region and market sector of projected Pegfilgrastim Biosimilar sales for 2023 through 2029. With Pegfilgrastim Biosimilar sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pegfilgrastim Biosimilar industry.

This Insight Report provides a comprehensive analysis of the global Pegfilgrastim Biosimilar landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pegfilgrastim Biosimilar portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Pegfilgrastim Biosimilar market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pegfilgrastim Biosimilar and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pegfilgrastim Biosimilar.

The global Pegfilgrastim Biosimilar market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Pegfilgrastim Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Pegfilgrastim Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Pegfilgrastim Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Pegfilgrastim Biosimilar players cover Novartis, Mylan, Coherus BioSciences, Mundipharma International, Biocon, Intas Pharmaceuticals, Pfizer and Dr Reddy’s Laboratories, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Pegfilgrastim Biosimilar market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

• Chemotherapy Treatment
• Transplantation

Segmentation by application

• Hospital Pharmacies
• Mail-Order Pharmacies
• Retail Pharmacies

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Novartis
• Mylan
• Coherus BioSciences
• Mundipharma International
• Biocon
• Intas Pharmaceuticals
• Pfizer
• Dr Reddy’s Laboratories

Key Questions Addressed in this Report

What is the 10-year outlook for the global Pegfilgrastim Biosimilar market?

What factors are driving Pegfilgrastim Biosimilar market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Pegfilgrastim Biosimilar market opportunities vary by end market size?

How does Pegfilgrastim Biosimilar break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Pegfilgrastim Biosimilar Annual Sales 2018-2029
  2.1.2 World Current & Future Analysis for Pegfilgrastim Biosimilar by Geographic Region, 2018, 2022 & 2029
  2.1.3 World Current & Future Analysis for Pegfilgrastim Biosimilar by Country/Region, 2018, 2022 & 2029
2.2 Pegfilgrastim Biosimilar Segment by Type
  2.2.1 Chemotherapy Treatment
  2.2.2 Transplantation
2.3 Pegfilgrastim Biosimilar Sales by Type
  2.3.1 Global Pegfilgrastim Biosimilar Sales Market Share by Type (2018-2023)
  2.3.2 Global Pegfilgrastim Biosimilar Revenue and Market Share by Type (2018-2023)
  2.3.3 Global Pegfilgrastim Biosimilar Sale Price by Type (2018-2023)
2.4 Pegfilgrastim Biosimilar Segment by Application
  2.4.1 Hospital Pharmacies
  2.4.2 Mail-Order Pharmacies
  2.4.3 Retail Pharmacies
2.5 Pegfilgrastim Biosimilar Sales by Application
  2.5.1 Global Pegfilgrastim Biosimilar Sale Market Share by Application (2018-2023)
  2.5.2 Global Pegfilgrastim Biosimilar Revenue and Market Share by Application (2018-2023)
  2.5.3 Global Pegfilgrastim Biosimilar Sale Price by Application (2018-2023)

3 GLOBAL PEGFILGRASTIM BIOSIMILAR BY COMPANY

3.1 Global Pegfilgrastim Biosimilar Breakdown Data by Company
  3.1.1 Global Pegfilgrastim Biosimilar Annual Sales by Company (2018-2023)
  3.1.2 Global Pegfilgrastim Biosimilar Sales Market Share by Company (2018-2023)
3.2 Global Pegfilgrastim Biosimilar Annual Revenue by Company (2018-2023)
  3.2.1 Global Pegfilgrastim Biosimilar Revenue by Company (2018-2023)
  3.2.2 Global Pegfilgrastim Biosimilar Revenue Market Share by Company (2018-2023)
3.3 Global Pegfilgrastim Biosimilar Sale Price by Company
3.4 Key Manufacturers Pegfilgrastim Biosimilar Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Pegfilgrastim Biosimilar Product Location Distribution
  3.4.2 Players Pegfilgrastim Biosimilar Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR PEGFILGRASTIM BIOSIMILAR BY GEOGRAPHIC REGION

4.1 World Historic Pegfilgrastim Biosimilar Market Size by Geographic Region (2018-2023)
  4.1.1 Global Pegfilgrastim Biosimilar Annual Sales by Geographic Region (2018-2023)
  4.1.2 Global Pegfilgrastim Biosimilar Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Pegfilgrastim Biosimilar Market Size by Country/Region (2018-2023)
  4.2.1 Global Pegfilgrastim Biosimilar Annual Sales by Country/Region (2018-2023)
  4.2.2 Global Pegfilgrastim Biosimilar Annual Revenue by Country/Region (2018-2023)
4.3 Americas Pegfilgrastim Biosimilar Sales Growth
4.4 APAC Pegfilgrastim Biosimilar Sales Growth
4.5 Europe Pegfilgrastim Biosimilar Sales Growth
4.6 Middle East & Africa Pegfilgrastim Biosimilar Sales Growth

5 AMERICAS

5.1 Americas Pegfilgrastim Biosimilar Sales by Country
  5.1.1 Americas Pegfilgrastim Biosimilar Sales by Country (2018-2023)
  5.1.2 Americas Pegfilgrastim Biosimilar Revenue by Country (2018-2023)
5.2 Americas Pegfilgrastim Biosimilar Sales by Type
5.3 Americas Pegfilgrastim Biosimilar Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Pegfilgrastim Biosimilar Sales by Region
  6.1.1 APAC Pegfilgrastim Biosimilar Sales by Region (2018-2023)
  6.1.2 APAC Pegfilgrastim Biosimilar Revenue by Region (2018-2023)
6.2 APAC Pegfilgrastim Biosimilar Sales by Type
6.3 APAC Pegfilgrastim Biosimilar Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Pegfilgrastim Biosimilar by Country
  7.1.1 Europe Pegfilgrastim Biosimilar Sales by Country (2018-2023)
  7.1.2 Europe Pegfilgrastim Biosimilar Revenue by Country (2018-2023)
7.2 Europe Pegfilgrastim Biosimilar Sales by Type
7.3 Europe Pegfilgrastim Biosimilar Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Pegfilgrastim Biosimilar by Country
  8.1.1 Middle East & Africa Pegfilgrastim Biosimilar Sales by Country (2018-2023)
  8.1.2 Middle East & Africa Pegfilgrastim Biosimilar Revenue by Country (2018-2023)
8.2 Middle East & Africa Pegfilgrastim Biosimilar Sales by Type
8.3 Middle East & Africa Pegfilgrastim Biosimilar Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Pegfilgrastim Biosimilar
10.3 Manufacturing Process Analysis of Pegfilgrastim Biosimilar
10.4 Industry Chain Structure of Pegfilgrastim Biosimilar

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Pegfilgrastim Biosimilar Distributors
11.3 Pegfilgrastim Biosimilar Customer

12 WORLD FORECAST REVIEW FOR PEGFILGRASTIM BIOSIMILAR BY GEOGRAPHIC REGION

12.1 Global Pegfilgrastim Biosimilar Market Size Forecast by Region
  12.1.1 Global Pegfilgrastim Biosimilar Forecast by Region (2024-2029)
  12.1.2 Global Pegfilgrastim Biosimilar Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Pegfilgrastim Biosimilar Forecast by Type
12.7 Global Pegfilgrastim Biosimilar Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Novartis
  13.1.1 Novartis Company Information
  13.1.2 Novartis Pegfilgrastim Biosimilar Product Portfolios and Specifications
  13.1.3 Novartis Pegfilgrastim Biosimilar Sales, Revenue, Price and Gross Margin (2018-2023)
  13.1.4 Novartis Main Business Overview
  13.1.5 Novartis Latest Developments
13.2 Mylan
  13.2.1 Mylan Company Information
  13.2.2 Mylan Pegfilgrastim Biosimilar Product Portfolios and Specifications
  13.2.3 Mylan Pegfilgrastim Biosimilar Sales, Revenue, Price and Gross Margin (2018-2023)
  13.2.4 Mylan Main Business Overview
  13.2.5 Mylan Latest Developments
13.3 Coherus BioSciences
  13.3.1 Coherus BioSciences Company Information
  13.3.2 Coherus BioSciences Pegfilgrastim Biosimilar Product Portfolios and Specifications
  13.3.3 Coherus BioSciences Pegfilgrastim Biosimilar Sales, Revenue, Price and Gross Margin (2018-2023)
  13.3.4 Coherus BioSciences Main Business Overview
  13.3.5 Coherus BioSciences Latest Developments
13.4 Mundipharma International
  13.4.1 Mundipharma International Company Information
  13.4.2 Mundipharma International Pegfilgrastim Biosimilar Product Portfolios and Specifications
  13.4.3 Mundipharma International Pegfilgrastim Biosimilar Sales, Revenue, Price and Gross Margin (2018-2023)
  13.4.4 Mundipharma International Main Business Overview
  13.4.5 Mundipharma International Latest Developments
13.5 Biocon
  13.5.1 Biocon Company Information
  13.5.2 Biocon Pegfilgrastim Biosimilar Product Portfolios and Specifications
  13.5.3 Biocon Pegfilgrastim Biosimilar Sales, Revenue, Price and Gross Margin (2018-2023)
  13.5.4 Biocon Main Business Overview
  13.5.5 Biocon Latest Developments
13.6 Intas Pharmaceuticals
  13.6.1 Intas Pharmaceuticals Company Information
  13.6.2 Intas Pharmaceuticals Pegfilgrastim Biosimilar Product Portfolios and Specifications
  13.6.3 Intas Pharmaceuticals Pegfilgrastim Biosimilar Sales, Revenue, Price and Gross Margin (2018-2023)
  13.6.4 Intas Pharmaceuticals Main Business Overview
  13.6.5 Intas Pharmaceuticals Latest Developments
13.7 Pfizer
  13.7.1 Pfizer Company Information
  13.7.2 Pfizer Pegfilgrastim Biosimilar Product Portfolios and Specifications
  13.7.3 Pfizer Pegfilgrastim Biosimilar Sales, Revenue, Price and Gross Margin (2018-2023)
  13.7.4 Pfizer Main Business Overview
  13.7.5 Pfizer Latest Developments
13.8 Dr Reddy’s Laboratories
  13.8.1 Dr Reddy’s Laboratories Company Information
  13.8.2 Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Product Portfolios and Specifications
  13.8.3 Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Sales, Revenue, Price and Gross Margin (2018-2023)
  13.8.4 Dr Reddy’s Laboratories Main Business Overview
  13.8.5 Dr Reddy’s Laboratories Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Pegfilgrastim Biosimilar Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Pegfilgrastim Biosimilar Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Chemotherapy Treatment
Table 4. Major Players of Transplantation
Table 5. Global Pegfilgrastim Biosimilar Sales by Type (2018-2023) & (K Units)
Table 6. Global Pegfilgrastim Biosimilar Sales Market Share by Type (2018-2023)
Table 7. Global Pegfilgrastim Biosimilar Revenue by Type (2018-2023) & ($ million)
Table 8. Global Pegfilgrastim Biosimilar Revenue Market Share by Type (2018-2023)
Table 9. Global Pegfilgrastim Biosimilar Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global Pegfilgrastim Biosimilar Sales by Application (2018-2023) & (K Units)
Table 11. Global Pegfilgrastim Biosimilar Sales Market Share by Application (2018-2023)
Table 12. Global Pegfilgrastim Biosimilar Revenue by Application (2018-2023)
Table 13. Global Pegfilgrastim Biosimilar Revenue Market Share by Application (2018-2023)
Table 14. Global Pegfilgrastim Biosimilar Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global Pegfilgrastim Biosimilar Sales by Company (2018-2023) & (K Units)
Table 16. Global Pegfilgrastim Biosimilar Sales Market Share by Company (2018-2023)
Table 17. Global Pegfilgrastim Biosimilar Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Pegfilgrastim Biosimilar Revenue Market Share by Company (2018-2023)
Table 19. Global Pegfilgrastim Biosimilar Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers Pegfilgrastim Biosimilar Producing Area Distribution and Sales Area
Table 21. Players Pegfilgrastim Biosimilar Products Offered
Table 22. Pegfilgrastim Biosimilar Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Pegfilgrastim Biosimilar Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global Pegfilgrastim Biosimilar Sales Market Share Geographic Region (2018-2023)
Table 27. Global Pegfilgrastim Biosimilar Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Pegfilgrastim Biosimilar Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Pegfilgrastim Biosimilar Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global Pegfilgrastim Biosimilar Sales Market Share by Country/Region (2018-2023)
Table 31. Global Pegfilgrastim Biosimilar Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Pegfilgrastim Biosimilar Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Pegfilgrastim Biosimilar Sales by Country (2018-2023) & (K Units)
Table 34. Americas Pegfilgrastim Biosimilar Sales Market Share by Country (2018-2023)
Table 35. Americas Pegfilgrastim Biosimilar Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Pegfilgrastim Biosimilar Revenue Market Share by Country (2018-2023)
Table 37. Americas Pegfilgrastim Biosimilar Sales by Type (2018-2023) & (K Units)
Table 38. Americas Pegfilgrastim Biosimilar Sales by Application (2018-2023) & (K Units)
Table 39. APAC Pegfilgrastim Biosimilar Sales by Region (2018-2023) & (K Units)
Table 40. APAC Pegfilgrastim Biosimilar Sales Market Share by Region (2018-2023)
Table 41. APAC Pegfilgrastim Biosimilar Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Pegfilgrastim Biosimilar Revenue Market Share by Region (2018-2023)
Table 43. APAC Pegfilgrastim Biosimilar Sales by Type (2018-2023) & (K Units)
Table 44. APAC Pegfilgrastim Biosimilar Sales by Application (2018-2023) & (K Units)
Table 45. Europe Pegfilgrastim Biosimilar Sales by Country (2018-2023) & (K Units)
Table 46. Europe Pegfilgrastim Biosimilar Sales Market Share by Country (2018-2023)
Table 47. Europe Pegfilgrastim Biosimilar Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Pegfilgrastim Biosimilar Revenue Market Share by Country (2018-2023)
Table 49. Europe Pegfilgrastim Biosimilar Sales by Type (2018-2023) & (K Units)
Table 50. Europe Pegfilgrastim Biosimilar Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa Pegfilgrastim Biosimilar Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa Pegfilgrastim Biosimilar Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Pegfilgrastim Biosimilar Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Pegfilgrastim Biosimilar Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Pegfilgrastim Biosimilar Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa Pegfilgrastim Biosimilar Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Pegfilgrastim Biosimilar
Table 58. Key Market Challenges & Risks of Pegfilgrastim Biosimilar
Table 59. Key Industry Trends of Pegfilgrastim Biosimilar
Table 60. Pegfilgrastim Biosimilar Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Pegfilgrastim Biosimilar Distributors List
Table 63. Pegfilgrastim Biosimilar Customer List
Table 64. Global Pegfilgrastim Biosimilar Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global Pegfilgrastim Biosimilar Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Pegfilgrastim Biosimilar Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas Pegfilgrastim Biosimilar Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Pegfilgrastim Biosimilar Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC Pegfilgrastim Biosimilar Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Pegfilgrastim Biosimilar Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe Pegfilgrastim Biosimilar Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Pegfilgrastim Biosimilar Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa Pegfilgrastim Biosimilar Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Pegfilgrastim Biosimilar Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global Pegfilgrastim Biosimilar Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Pegfilgrastim Biosimilar Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global Pegfilgrastim Biosimilar Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Novartis Basic Information, Pegfilgrastim Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 79. Novartis Pegfilgrastim Biosimilar Product Portfolios and Specifications
Table 80. Novartis Pegfilgrastim Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. Novartis Main Business
Table 82. Novartis Latest Developments
Table 83. Mylan Basic Information, Pegfilgrastim Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 84. Mylan Pegfilgrastim Biosimilar Product Portfolios and Specifications
Table 85. Mylan Pegfilgrastim Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. Mylan Main Business
Table 87. Mylan Latest Developments
Table 88. Coherus BioSciences Basic Information, Pegfilgrastim Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 89. Coherus BioSciences Pegfilgrastim Biosimilar Product Portfolios and Specifications
Table 90. Coherus BioSciences Pegfilgrastim Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. Coherus BioSciences Main Business
Table 92. Coherus BioSciences Latest Developments
Table 93. Mundipharma International Basic Information, Pegfilgrastim Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 94. Mundipharma International Pegfilgrastim Biosimilar Product Portfolios and Specifications
Table 95. Mundipharma International Pegfilgrastim Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. Mundipharma International Main Business
Table 97. Mundipharma International Latest Developments
Table 98. Biocon Basic Information, Pegfilgrastim Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 99. Biocon Pegfilgrastim Biosimilar Product Portfolios and Specifications
Table 100. Biocon Pegfilgrastim Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. Biocon Main Business
Table 102. Biocon Latest Developments
Table 103. Intas Pharmaceuticals Basic Information, Pegfilgrastim Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 104. Intas Pharmaceuticals Pegfilgrastim Biosimilar Product Portfolios and Specifications
Table 105. Intas Pharmaceuticals Pegfilgrastim Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. Intas Pharmaceuticals Main Business
Table 107. Intas Pharmaceuticals Latest Developments
Table 108. Pfizer Basic Information, Pegfilgrastim Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 109. Pfizer Pegfilgrastim Biosimilar Product Portfolios and Specifications
Table 110. Pfizer Pegfilgrastim Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. Pfizer Main Business
Table 112. Pfizer Latest Developments
Table 113. Dr Reddy’s Laboratories Basic Information, Pegfilgrastim Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 114. Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Product Portfolios and Specifications
Table 115. Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. Dr Reddy’s Laboratories Main Business
Table 117. Dr Reddy’s Laboratories Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Pegfilgrastim Biosimilar
Figure 2. Pegfilgrastim Biosimilar Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Pegfilgrastim Biosimilar Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Pegfilgrastim Biosimilar Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Pegfilgrastim Biosimilar Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Chemotherapy Treatment
Figure 10. Product Picture of Transplantation
Figure 11. Global Pegfilgrastim Biosimilar Sales Market Share by Type in 2022
Figure 12. Global Pegfilgrastim Biosimilar Revenue Market Share by Type (2018-2023)
Figure 13. Pegfilgrastim Biosimilar Consumed in Hospital Pharmacies
Figure 14. Global Pegfilgrastim Biosimilar Market: Hospital Pharmacies (2018-2023) & (K Units)
Figure 15. Pegfilgrastim Biosimilar Consumed in Mail-Order Pharmacies
Figure 16. Global Pegfilgrastim Biosimilar Market: Mail-Order Pharmacies (2018-2023) & (K Units)
Figure 17. Pegfilgrastim Biosimilar Consumed in Retail Pharmacies
Figure 18. Global Pegfilgrastim Biosimilar Market: Retail Pharmacies (2018-2023) & (K Units)
Figure 19. Global Pegfilgrastim Biosimilar Sales Market Share by Application (2022)
Figure 20. Global Pegfilgrastim Biosimilar Revenue Market Share by Application in 2022
Figure 21. Pegfilgrastim Biosimilar Sales Market by Company in 2022 (K Units)
Figure 22. Global Pegfilgrastim Biosimilar Sales Market Share by Company in 2022
Figure 23. Pegfilgrastim Biosimilar Revenue Market by Company in 2022 ($ Million)
Figure 24. Global Pegfilgrastim Biosimilar Revenue Market Share by Company in 2022
Figure 25. Global Pegfilgrastim Biosimilar Sales Market Share by Geographic Region (2018-2023)
Figure 26. Global Pegfilgrastim Biosimilar Revenue Market Share by Geographic Region in 2022
Figure 27. Americas Pegfilgrastim Biosimilar Sales 2018-2023 (K Units)
Figure 28. Americas Pegfilgrastim Biosimilar Revenue 2018-2023 ($ Millions)
Figure 29. APAC Pegfilgrastim Biosimilar Sales 2018-2023 (K Units)
Figure 30. APAC Pegfilgrastim Biosimilar Revenue 2018-2023 ($ Millions)
Figure 31. Europe Pegfilgrastim Biosimilar Sales 2018-2023 (K Units)
Figure 32. Europe Pegfilgrastim Biosimilar Revenue 2018-2023 ($ Millions)
Figure 33. Middle East & Africa Pegfilgrastim Biosimilar Sales 2018-2023 (K Units)
Figure 34. Middle East & Africa Pegfilgrastim Biosimilar Revenue 2018-2023 ($ Millions)
Figure 35. Americas Pegfilgrastim Biosimilar Sales Market Share by Country in 2022
Figure 36. Americas Pegfilgrastim Biosimilar Revenue Market Share by Country in 2022
Figure 37. Americas Pegfilgrastim Biosimilar Sales Market Share by Type (2018-2023)
Figure 38. Americas Pegfilgrastim Biosimilar Sales Market Share by Application (2018-2023)
Figure 39. United States Pegfilgrastim Biosimilar Revenue Growth 2018-2023 ($ Millions)
Figure 40. Canada Pegfilgrastim Biosimilar Revenue Growth 2018-2023 ($ Millions)
Figure 41. Mexico Pegfilgrastim Biosimilar Revenue Growth 2018-2023 ($ Millions)
Figure 42. Brazil Pegfilgrastim Biosimilar Revenue Growth 2018-2023 ($ Millions)
Figure 43. APAC Pegfilgrastim Biosimilar Sales Market Share by Region in 2022
Figure 44. APAC Pegfilgrastim Biosimilar Revenue Market Share by Regions in 2022
Figure 45. APAC Pegfilgrastim Biosimilar Sales Market Share by Type (2018-2023)
Figure 46. APAC Pegfilgrastim Biosimilar Sales Market Share by Application (2018-2023)
Figure 47. China Pegfilgrastim Biosimilar Revenue Growth 2018-2023 ($ Millions)
Figure 48. Japan Pegfilgrastim Biosimilar Revenue Growth 2018-2023 ($ Millions)
Figure 49. South Korea Pegfilgrastim Biosimilar Revenue Growth 2018-2023 ($ Millions)
Figure 50. Southeast Asia Pegfilgrastim Biosimilar Revenue Growth 2018-2023 ($ Millions)
Figure 51. India Pegfilgrastim Biosimilar Revenue Growth 2018-2023 ($ Millions)
Figure 52. Australia Pegfilgrastim Biosimilar Revenue Growth 2018-2023 ($ Millions)
Figure 53. China Taiwan Pegfilgrastim Biosimilar Revenue Growth 2018-2023 ($ Millions)
Figure 54. Europe Pegfilgrastim Biosimilar Sales Market Share by Country in 2022
Figure 55. Europe Pegfilgrastim Biosimilar Revenue Market Share by Country in 2022
Figure 56. Europe Pegfilgrastim Biosimilar Sales Market Share by Type (2018-2023)
Figure 57. Europe Pegfilgrastim Biosimilar Sales Market Share by Application (2018-2023)
Figure 58. Germany Pegfilgrastim Biosimilar Revenue Growth 2018-2023 ($ Millions)
Figure 59. France Pegfilgrastim Biosimilar Revenue Growth 2018-2023 ($ Millions)
Figure 60. UK Pegfilgrastim Biosimilar Revenue Growth 2018-2023 ($ Millions)
Figure 61. Italy Pegfilgrastim Biosimilar Revenue Growth 2018-2023 ($ Millions)
Figure 62. Russia Pegfilgrastim Biosimilar Revenue Growth 2018-2023 ($ Millions)
Figure 63. Middle East & Africa Pegfilgrastim Biosimilar Sales Market Share by Country in 2022
Figure 64. Middle East & Africa Pegfilgrastim Biosimilar Revenue Market Share by Country in 2022
Figure 65. Middle East & Africa Pegfilgrastim Biosimilar Sales Market Share by Type (2018-2023)
Figure 66. Middle East & Africa Pegfilgrastim Biosimilar Sales Market Share by Application (2018-2023)
Figure 67. Egypt Pegfilgrastim Biosimilar Revenue Growth 2018-2023 ($ Millions)
Figure 68. South Africa Pegfilgrastim Biosimilar Revenue Growth 2018-2023 ($ Millions)
Figure 69. Israel Pegfilgrastim Biosimilar Revenue Growth 2018-2023 ($ Millions)
Figure 70. Turkey Pegfilgrastim Biosimilar Revenue Growth 2018-2023 ($ Millions)
Figure 71. GCC Country Pegfilgrastim Biosimilar Revenue Growth 2018-2023 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Pegfilgrastim Biosimilar in 2022
Figure 73. Manufacturing Process Analysis of Pegfilgrastim Biosimilar
Figure 74. Industry Chain Structure of Pegfilgrastim Biosimilar
Figure 75. Channels of Distribution
Figure 76. Global Pegfilgrastim Biosimilar Sales Market Forecast by Region (2024-2029)
Figure 77. Global Pegfilgrastim Biosimilar Revenue Market Share Forecast by Region (2024-2029)
Figure 78. Global Pegfilgrastim Biosimilar Sales Market Share Forecast by Type (2024-2029)
Figure 79. Global Pegfilgrastim Biosimilar Revenue Market Share Forecast by Type (2024-2029)
Figure 80. Global Pegfilgrastim Biosimilar Sales Market Share Forecast by Application (2024-2029)
Figure 81. Global Pegfilgrastim Biosimilar Revenue Market Share Forecast by Application (2024-2029)